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Abstract. Background: Fibroblast activation protein-alpha
(FAPα) is a type-II integral membrane serine protease and
is expressed in most stromal fibroblasts. Recent studies
showed that FAPα is also expressed in certain cancer cells
but its role is still uncertain. Materials and Methods: We
analyzed the non-enzymatic activity of FAPα in breast cancer
cells by introducing an enzymatic mutant FAPα (FAPS624A),
in which the serine catalytic triad was destroyed. FAPα
overexpression and knockdown cells were generated as
controls. Results: Cellular growth and motility were
markedly increased in MCF-7 cells overexpressing FAPα and
enzymatic-mutant FAPS624A. This is consistent with
observations in FAPα-silenced BT549 cells. Western blotting
showed activation of phosphatidylinositol-3-kinase (PI3K)/
protein kinase B (AKT) and matrix metalloproteinase (MMP)
2/9 in both wild-type FAPα-overexpressing and enzymatic-
mutant FAPS624A-overexpressing cells. Conclusion:
Promotion of cellular growth and motility is independent of
the enzymatic activity of FAPα in breast cancer cells. The
PI3K/AKT and MMP2/9 signaling pathways might be
involved in such regulation.
Human fibroblast activation protein-alpha (FAPα, also
known as seprase) is a type-II integral membrane serine
protease belonging to the prolyl-cleaving peptidase family
with post-prolyldipeptidyl peptidase and gelatinase activity
(1, 2). It is a 170-kDa homodimeric glycoprotein consisting
of two N-glycosylated 97 kDa subunits. Studies have shown
that FAPα is primarily expressed in fetal mesenchymal
tissues, wounded tissues, and stromal fibroblasts of more
than 90% of malignant epithelial tumors. However, benign
tumors or normal adult tissues, except bone marrow
mesenchymal cells, are generally FAPα-negative (3-5).
Through its gelatinase activity, FAPα degrades extracellular
matrix and promotes growth and invasion of cancer cells (6,
7). Elevated expression of FAPα in stromal fibroblasts is
associated with poor prognosis and increased metastasis in a
number of cancer types, including colonic (8), pancreatic (9),
ovarian (10), lung (11), and gastric (12) cancer. This makes
FAPα a novel prognostic biomarker and a potential
therapeutic target in cancer. 
Furthermore, an increasing number of studies have
demonstrated that FAPα expression is not confined to
stromal fibroblasts. The molecule was also found in many
epithelia-derived cancer cells including breast (13), gastric
(14), ovarian (15), and pancreatic (16) cancer. Thus, the role
of cancer cell expression of FAPα is of great interest. It has
been noted that cancer cell-expressed FAPα had non-
enzymatic functions. Huang et al. found that inhibitors of
prolylpeptidase did not slow the growth of tumors produced
by FAPα-expressing breast cancer cells in an animal model.
The study also showed that breast cancer cells expressing a
catalytically inactive mutant of FAPα also produced tumors
that grew rapidly (17). Yang et al. reported that FAPα with
integrin α3β1 and the urokinase-type plasminogen activator
receptor (uPAR) signaling complex mediated ovarian cancer
cell migration via the small GTPase Ras-related C3
botulinum toxin substrate 1 (RAC1) pathway. FAPα-
mediated up-regulation of phosphorylated extracellular
signal-regulated kinase (ERK) occurred in a time-dependent
manner (18). Wang et al. found that silencing FAPα inhibited
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the growth and metastasis of oral squamous cell carcinoma
(OSCC) cells in vitro and in vivo. In addition, knockdown of
FAPα inactivated phosphatase and tensin homolog
(PTEN)/phosphatidylinositol-3-kinase (PI3K)/protein kinase
B (AKT) and rat sarcoma viral oncogene homolog (RAS)-
ERK signaling pathway and resulted in down-regulation of
proliferation, migration, and invasion by OSCC cells (19).
In the present study, we analyzed the role of FAPα in
regulating breast cancer cell growth, adhesion, invasion and
migration. To ascertain whether FAPα has non-enzymatic
functions in the regulation of cell growth and motility, an
enzymatic mutant of FAPα by site-directed mutagenesis at
the catalytic site 624th serine (serine replaced with alanine)
to destroy the gelatinase activity was set as a control. The
potential signaling pathway involved in the function of FAPα
in breast cancer cells was also explored. 
Materials and Methods
Cell lines. Human breast cancer cells, MCF-7 and BT549 were
obtained from the American Type Cell Collection (ATCC,
Manassas, VA, USA). Cells were routinely cultured with
Dulbecco’s modified Eagle medium (DMEM) supplemented with
10% fetal calf serum, penicillin and streptomycin (Gibco BRC,
Paisley, Scotland, UK).
FAPα expression constructs. cDNA of FAPα was generated from
normal human prostate tissues by reverse transcription polymerase
chain reaction (RT-PCR) using the primers: 5’-TTA GTC TGA
CAA AGA GAA ACA CTG and 5’-ATG AAG ACT TGG GTA
AAA ATC G. The serine at 624 site in the catalytic triad of FAPα
was substituted for alanine using QuikChange® II Site-Directed
Mutagenesis kit (Stratagene, La Jolla, CA, USA) and forward
primer: 5’-GAA TAG CCA TAT GGG GCT GGT CCT ATG GAG
GAT ACG TTT C, reverse primer: 5’-GAA TAG CCA TAT GGG
GCT GGG CCT ATG GAG GAT ACG TTT C. Full-length wild-
type FAP and mutant type FAPS624A were then cloned into a
pEF6/V5-His vector (Invitrogen, Paisley, Scotland, UK). Multiple
clones of Escherichia coli were screened and plasmids from the
clones were sequenced. 
Short hairpin RNA (shRNA) interference of FAPα. Four shRNA
sequences targeting the FAPα gene were designed and synthesized
by Shanghai Jima Pharmaceutical Technology, China. The four
shRNA sequences of FAPα and the negative control sequence are
listed in Table I.
Plasmid transfection. Breast cancer cells MCF-7 and BT549 were
cultured in DMEM. Lipofectamine LTX and Plus Reagent
(Invitrogen) were used to transfect FAPα expression constructs and
shRNA into breast cancer cells according to the manufacturer’s
protocol. The medium containing transfection reagents was replaced
with DMEM supplemented with 10% FBS at 18 h after the
transfection. The cells were collected at 48 h after the transfection,
processed for the following experiments, and then prepared for
protein extraction. The overexpression and silencing efficiency of
FAPα was tested by RT-PCR and western blot.
RT-qPCR analysis of FAPα expression. Total RNA was extracted
and reverse-transcribed into cDNA using M-MLV-RTase (Promega,
Madison, WI, USA). The resulting cDNA was used for PCR, which
employed a SYBR-Green Master PCR Mix (Applied Biosystem,
Carlsbad, CA, USA) in triplicates. Primers for qRT-PCR were as
follows: Forward primer: 5’-TGT GCA TTG TCT TAC GCC CT,
reverse primer: 5’-CCG ATC AGG TGA TAA GCC GT.
Glyceraldehyde 3-phosphate dehydrogenase (GAPDH) was used as
an internal control to normalize FAP expression (forward primer:
5’-GGC TGC TTT TAA CTC TGG TA, reverse primer: 5’-GAC
TGT GGT CAT GAG TCC TT). Differential expression of FAP was
calculated using the 2-ΔΔCt method.
Western blotting. Confluent cells were harvested using the
EDTA/Trypsin method, pelleted and then lysed using a lysis buffer
containing 2.4 mg/ml Tris, 4.4 mg/ml NaCl, 5 mg/ml sodium
deoxycholate, 20 μg/ml sodium azide, 1.5% Triton, 100 μg/ml
phenylmethylsulfonyl fluoride, 1 μg/ml leupeptin, and 1 μg/ml
aprotinin, for 45 min at 4˚C. After lysis and centrifugation at 10,000
× g for 15 min to remove the insolubles, protein concentrations for
each sample were measured using an improved Lowry assay (DC
Protein Assay kit; Bio-Rad Laboratories, Hercules, CA, USA). The
samples were adjusted to equal protein concentrations with sample
buffer and then boiled at 100˚C for 5 min, before being separated
on a 10% polyacrylamide gel. Following electrophoresis, these
separated protein samples were transferred to phenylmethylsulfonyl
fluoride membranes (Millipore, Kankakee, IL, USA) and proteins
detected with appropriate primary antibodies including those against
FAPα (LifeSpan BioSciences Inc., Seattle, WA, USA), GAPDH
(Santa Cruz Biotechnology, Santa Cruz, CA, USA), AKT, p-AKT
(Ser-473), PI3K, p-PI3K (Tyr-458), matrix metalloproteinase
(MMP)2 and MMP9 (Cell Signaling Technology, Danvers, MA,
USA) at a concentration of 1:300, and specific peroxidase-
conjugated secondary antibodies at a concentration of 1:1,000. The
protein signals were detected using SuperSignal West Dura
Extended Duration Substrate (Pierce, Rockford, IL, USA). 
3-(4,5-Dimethyl-2-thiazolyl)-2,5-diphenyl-2-H-tetrazolium (MTT)
assay. Cells were grown in exponential phase and detached by
trypsin/EDTA treatment. Viable cells (2,000 cells/ml) were plated
into 96-well tissue culture plates (100 μl complete medium/well)
and cultured at 37˚C in 5% CO2. At different time points, MTT
reagent was added (10 μl per well) and cells incubated at 37˚C for
a further 4 h. The reaction was stopped with addition of 100 μl
dimethyl sulfoxide and the optical density was determined at
OD570 nm on a multi-well plate reader. 
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Table I. Interference sequence of short hairpin RNA (shRNA) for
fibroblast activation protein-alpha (FAPα). CON-sh: Control shRNA.
shRNA Sequence (5’-3’)
shRNA288 GCC CTT CAA GAG TTC ATA ACT
shRNA506 GCT TCA AAT TAC GGC TTA TCA
shRNA672 GGT CGC CTG TTG GGA GTA AAT
shRNA839 GCT CTC TGG TGG TCT CCT AAT
CON-sh GTT CTC CGA ACG TGT CAC GT
Cell-matrix adhesion assay. A 96-well plate was pre-coated with 5
μg of Matrigel (Collaborative Research Products, Bedford, MA,
USA) and allowed to dry overnight. Following rehydration with
serum-free medium, 20,000 cells were seeded into each well. After
40 min of incubation, non-adherent cells were washed off using
balanced salt solution buffer. The remaining cells were fixed with
4% formalin and stained with 0.5% crystal violet. The number of
adherent cells was then counted under microscopy.
In vitro invasion assay. Transwell inserts (Becton Dickinson Labware,
Oxford, UK) with 8 μm pore size were coated with 50 μg of Matrigel
and air-dried. Following rehydration with serum-free medium, cells
were seeded at a density of 30,000 per insert. After 3 days’ incubation,
cells that had migrated through the matrix and adhered to the other
side of the insert were fixed in 4% formalin, stained with 0.5%
(weight/volume) crystal violet, and counted under a microscope.
Migration/wound-healing assay. Cells were seeded into a 6-well
plate and allowed to reach confluence. The monolayer of cells was
then scraped with a P-200 pipette tip to create a wound of
approximately 200 μm. Fresh medium supplemented with 5% FBS
was added, and the wound-closing procedure was observed for 12 h.
Photographs were taken at 0, 6 and 12 h, respectively.
Statistical analysis. Data from all quantitative assays were expressed
as mean±SD. One-way ANOVA and independent-samples t-test
were used to evaluate difference between groups in all tests
performed, with the resultant p-value representing a two-sided test
of statistical significance. All statistical analyses were performed
and visualized by GraphPad Prism 5.0. A value of p<0.05 was
considered statistically significant.  
Results
FAPα overexpression and knockdown in breast cancer cell
lines. To identify the oncogenic function of FAPα in breast
cancer, we utilized shRNA to silence FAPα expression in
BT549 cells, an FAPα-positive human breast cancer cell
line. Knockdown efficiency was evaluated by both RT-
qPCR and western blotting. The results showed that FAPα
expression was reduced by 90% in BT549 cells after
transfection with shRNA 288 (Figure 1). In addition, FAPα
and its enzymatic mutant type FAPS624A were transfected
into MCF-7 breast cancer cells, an FAPα-null cell line. As
shown in Figure 1, overexpression of both wild-type FAPα
and mutant-type FAPS624A in MCF-7 cells was
successfully established. 
Effects of FAPα expression on cell growth. We first
determined the effect of FAPα overexpression on cell growth
in vitro (Figure 2A). Overexpression of FAPα in MCF-7
cells significantly increased the growth rate at day 3
(p=0.006) and day 5 (p=0.002) relative to the control. The
growth rate was also raised by overexpression of FAPS624A
in MCF-7 cells at day 3 (p<0.001) and day 5 (p<0.001).
The effects of FAPα expression on cell growth of MCF-7
cells were consistent with observations in BT549 cells.
Knockdown of FAPα resulted in a dramatic reduction in cell
growth rate at day 5 (p=0.004). However, the absence of FAPα
did not lead to a significantly decreased growth rate at day 3.
Effects of FAPα expression on cell adhesion. The influence
of FAPα on the adhesiveness of breast cancer cells to matrix
proteins was also determined. As shown in Figure 2B,
overexpression of both FAPα and mutant FAPS624A in
MCF-7 cells significantly enhanced the adhesive properties
compared with control cells (p=0.0014 and p=0.011,
respectively). Conversely, knockdown of FAPα led to a
significant reduction in adhesive ability (p=0.044).
Effects of FAPα expression on cell invasion. Matrigel
invasion assay was used to evaluate the invasive capability
of breast cancer cells. As shown in Figure 2C, MCF-7 cells
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Figure 1. Determination of the overexpression and knockdown efficiency
of fibroblast activation protein-alpha (FAPα) in breast cancer cells.
FAPα expression was reduced by 90% in BT549 cells after transfection
with shRNA 288. Wild-type FAPα and its enzymatic mutant type
FAPS624A-overexpressing MCF-7 cells were successfully established.
A: FAPα expression was examined by western blotting. B: Reverse
transcription qualitative real-time polymerase chain reaction was
performed to determine the expression of FAPα.
overexpressing FAPα were significantly more invasive than
the control cells (p=0.013). The presence of FAPS624A
also increased the invasive capability of MCF-7 cells, but
without statistical significance (p=0.096). The effect of
FAPα on invasiveness was also confirmed in FAPα-
knockdown BT549 cells. The absence of FAPα in BT549
cells led to a relatively lower invasive capability than that
of control cells (p=0.038).
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Figure 2. Effects of fibroblast activation protein-alpha (FAPα) expression on cellular function in breast cancer cells. A: 3-(4,5-dimethyl-2-thiazolyl)-
2,5-diphenyl-2-H-tetrazolium assay showed that overexpression of wild-type FAPα or mutant type FAPS624A increased the growth rate of MCF-7
cells at day 3 (FAP vs. CON: p=0.006. FAPS624A vs. CON: p<0.001) and day 5 (FAP vs. CON: p=0.002. FAPS624A vs. CON: p<0.001), while
knockdown of FAPα dramatically reduced the growth rate of BT549 cells at day 5 (shRNA vs. CON: p=0.004). B: Cell-matrix adhesion assay
revealed that overexpression of wild-type FAPα or mutant type FAPS624A in MCF-7 cells also significantly enhanced the adhesive properties (FAP
vs. CON: p=0.0014. FAPS624A vs. CON: p=0.011), while knockdown of FAPα reduced the adhesive ability of BT549 cells (shRNA vs. CON:
p=0.044). C: Matrigel invasion assay showed that MCF-7 cells overexpressing wild-type FAPα were significantly more invasive (FAP vs. CON:
p=0.013), while absence of FAPα in BT549 cells led to a lower invasive capability (shRNA vs. CON: p=0.038). However, the presence of FAPS624A
in MCF-7 cells increased the invasive capability but without statistical difference (FAPS624A vs. CON: p=0.096). D: Wound-healing assay showed
that overexpression of wild-type FAPα and mutant FAPS624A markedly increased the migration capability of MCF-7 cells at 6 h (FAP vs. CON:
p=0.002. FAPS624A vs. CON: p<0.001) and 12 h (FAP vs. CON: p=0.016. FAPS624A vs. CON: p=0.0014). Absence of FAPα significantly reduced
the migration capability of BT-549 cells at 12 h (shRNA vs. CON: p=0.0044). 
Effects of FAPα expression on cell migration. The wound-
healing assay was employed to examine the influence of
FAPα on cell migration. As shown in Figure 2D,
overexpression of FAPα in MCF-7 cells markedly elevated
the migration capability of MCF-7 cells at 6 h (p=0.002) and
12 h (p=0.016). The presence of enzymatic mutant
FAPS624A also dramatically enhanced the motility of MCF-
7 cells at 6 h (p<0.001) and 12 h (p=0.0014). The result was
also consistent with observations in FAPα-knockdown cells.
The absence of FAPα in BT549 cells significantly reduced
migration capability at 12 h (p=0.0044). However, a marked
decline in motility of BT549 cells was not seen at 6 h.
FAPα regulates cellular functions through PI3K/AKT and
MMP2/9 pathway. To explore whether the effects of FAPα
on the cellular functions of breast cancer cells were
associated with the PI3K/AKT pathway, western blotting was
performed to detect expression of total AKT and PI3K,
phosphorylated AKT (p-AKT) and phosphorylated PI3K (p-
PI3K) protein. As shown in Figure 3, expression of p-AKT
and p-PI3K was markedly increased in MCF-7 cells
expressing the wild-type FAPα and enzymatic mutant
FAPS624A. However, protein levels of total AKT and PI3K
were not dramatically altered. The impact of FAPα on
MMP2 and MMP9 expression of MCF-7 cells was also
examined. Overexpression of FAPα and FAPS624A in MCF-
7 cells increased the levels of MMP2 and MMP9 compared
to control cells. 
Discussion
Recent studies have provided evidence that FAPα may be
involved in the development of over 90% of epithelial
cancers and that the protein may have a potential value in
both diagnosis and treatment of cancer (11, 20). Previous
studies tended to analyze the localization and expression of
this protease in diverse malignancies. It is noteworthy that
there appears to be a clear discrepancy between the location
and expression of FAPα in tissues from different tumor
types (6). Some studies demonstrated that FAPα expressed
by stromal fibroblast could promote cancer cell invasion and
metastasis by degrading surrounding stroma and
extracellular matrix though its gelatinase activity (8-12).
However, there is increasing evidence showing that FAPα
expressed by epithelial cancer cells in fact directly promoted
cell proliferation, migration, and invasion and that this effect
of FAPα was independent of its enzymatic activity (13-16).
In the current study, we clearly demonstrated that
overexpression of FAPα markedly increased cell growth,
adhesion, invasion and migration in MCF-7 breast cancer
cells. When expression of FAPα in BT549 breast cancer cells
was silenced, growth, adhesion, invasion and migration were
reduced. The results were consistent with the observations in
other cancer types including ovarian (18), breast (21), and
oral and esophageal squamous cell carcinoma (19, 22). This
suggests that cancer cell-expressed FAPα does indeed affect
the biological behavior of cancer cells by acting as potential
tumor stimulus.
FAPα has been shown to have two proteolytic activities:
a gelatinase and an N-terminal post-prolyl amino peptidase
that can cleave Ala-Pro- 7-amino-4-trifluoromethyl
coumarin. Both the gelatinase and dipeptidyl peptidase
(DPP) activities of FAPα are mediated by an active 624-site
serine (23, 24). Cheng et al. reported that site-directed
mutagenesis at the 624 catalytic site of FAPα, Ser624 to
Ala624, resulted in an approximately 100,000-fold loss of
FAPα protein DPP activity. The reduced enzymatic activity
was associated with decreased tumor growth rates and
tumorigenicity in HEK293 cells transfected with FAPS624A
compared with cells transfected with wild-type FAPα (25).
However, in another study, breast cancer cells expressing a
catalytically inactive mutant FAPS624A produced tumors
that grew rapidly in an SCID mouse model. It is also
interesting to note that inhibitors of prolylpeptidases did not
slow the growth of tumors (17). In the current study, as in
wild-type FAPα-expressing cells, the enzymatic mutant
FAPα (FAPS624A) overexpressed in MCF-7 cells also
promotes cell proliferation, adhesion, and migration. Thus
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Figure 3. Influence of fibroblast activation protein-alpha (FAPα)
overexpression on phosphatidylinositol-3-kinase (PI3K)/ protein kinase
B (AKT) and matrix metalloproteinase (MMP) 2/9 pathway by western
blotting. Compared to control cells (CON), expression of phosphor (p)-
AKT and p-PI3K was markedly increased in both wild-type FAPα and
enzymatic-mutant FAPS624A-overexpressing MCF-7 cells, while
expression of total AKT and PI3K protein was not dramatically altered.
Expression of MMP2 and MMP9 was also increased in wild-type FAPα
and enzymatic mutant FAPS624A-overexpressing MCF-7 cells.
our study, together with that of Huang et al. (17), clearly
indicate that the tumorigenicity of FAPα is not confined to
its enzymatic activity. 
It has been recently reported that beyond its proposed
enzymatic activities, FAPα expressed by epithelial cancer
cells may engage with cell signaling pathways. Wang et al.
found that the enzyme activity of FAP was not required for
cell adhesion and migration. Overexpression of FAP
increased the expression of MMP2 and reduced expression of
integrin-β1 in 293T cells (26). Santos et al. found that colonic
cancer cell CT26-transplanted tumors from FAPα-null mice
showed an increase in phosphor focal adhesion kinase (FAK)
Tyr397, phospho-ERK (p44/42) and p21WAF1 compared to
tumors form wild-type mice. The effect of FAP depletion was
fully recapitulated in the endogenous lung tumor model (27).
Yang et al. reported that FAPα with integrin-α3β1 and the
uPAR signaling complex mediated ovarian cancer cell
migration via the small GTPase RAC1 pathway (18). In
another study, knockdown of FAPα in OSCC cells inactivated
PTEN/PI3K/AKT and RAS-ERK signaling pathway and
resulted in down-regulation of proliferation, migration, and
invasion in OSCC cells (19). Besides FAPα expressed by
cancer cells, FAPα expressed by stromal cells was also
reported to participate in regulation of signaling pathway such
as RhoA (28), β-catenin (29), and fibroblast growth factor 1/
fibroblast growth factor receptor 3 (30).
In our study, we also investigated the potential mechanisms
underlying the effects of FAPα in breast cancer. Our results
showed that although the levels of total PI3K and AKT protein
were not altered, p-AKT and p-PI3K were however markedly
increased in both wild-type FAPα and enzymatic mutant
FAPS624A overexpressing MCF-7 cells. Expression of MMP2
and MMP9 was also elevated in such MCF-7 cells. The
PI3K/AKT signaling pathway plays an important role in cell
proliferation and motility. The PI3K/AKT signaling pathway
is up-regulated in most epithelial cancers and its activation
promotes proliferation of cancer cells (31). The complex
interactions of cancer cells with extracellular matrix are also
crucial in regulating cell motility (32). As a critical factor
mediating the interactions of cells with the extracellular
matrix, the MMP family is thought to be an important
determinant in cell migration. MMP2 and MMP9 are two key
members of the MMP family that facilitate cell invasion and
metastasis in most solid human cancer types (33-35). Together
with the observations reported, it is strongly indicated that
FAPα is actively involved in the activation/phosphorylation of
these signaling proteins rather than in the transcriptional
regulation of these signaling mediators. 
The mechanism(s) by which FAPα expressed by epithelial
cancer cells regulates cell signaling pathways is still
uncertain. As a transmembrane protein, FAPα has similar
structural homology to DPPIV (CD26). In DPPIV, the N-
terminal hydrophobic sequence represents an uncleavable
signal peptide that also functions as a membrane-anchoring
domain (36). Indeed, it has been reported that DPPIV may
serve as a receptor and participate in regulation of signaling
pathways (37, 38). Thus it is highly plausible to hypothesize
that FAPα has possibly a similar role, as a signaling peptide
(6, 39). 
Conclusion
Our study provides evidence that FAPα promotes cell
growth, adhesion, invasion and migration in breast cancer.
Its regulatory effects are independent of its enzymatic
activity. The PI3K/AKT and MMP2/9 signaling pathway
might be involved in the effects of FAPα on breast cancer
cells.
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